Squamous Cell Carcinoma of the Paranasal Sinuses: A Single Center Experience

Abstract

Objective Squamous cell carcinoma (SCC) of the paranasal sinuses is usually diagnosed at an advanced stage, making curative therapy difficult. The goal of this study was to evaluate the management and outcomes of patients with SCC treated at our institution. Methods In a population-based consecutive prospective cohort, we conducted an analysis of all patients treated for SCC between 1988 and 2017. Results A total of 72 patients were included, follow-up was 100%. Mean follow-up was 57 months for the entire cohort, and 108 months for patients with no evidence of disease. Eighty-two percent of all patients had high-stage (T4) disease. Fifty-seven patients underwent treatment with curative intent; consisting of surgery with or without oncologic treatment in 34, and of oncologic treatment only in 23 cases. Fifteen patients received palliative treatment. The rates of overall survival for the entire cohort were 55% at 2, 41% at 5, and 32% at 10 years, and corresponding disease-specific survival (DSS) rates were 55, 45, and 34%, respectively. DSS rates after surgical treatment with curative intent were 81% at 2, 65% at 5, and 54% at 10 years. Retromaxillary involvement and nonradical surgery were negative prognostic factors. Best survival was achieved with the combination of radical surgery and adjuvant oncologic treatment. Conclusion Surgical resection with a curative intent yielded 65% at 5-year DSS even in this cohort of patients with high-stage SCC and is still considered as the treatment of choice, preferably in combination with adjuvant radiation therapy and chemotherapy.

International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors

“…found that close or positive margins within the PPF or ITF were associated with worse 5‐year RFS (hazard ratio [HR] 6.158, p = 0.001) and OS (HR 21.961, p = 0.006) 191 . Similar effects were reported by Konig et al., where retromaxillary involvement was associated with worse survival at 2, 5, and 10 years (35%, 29%, and 17%, respectively) 193 . In contrast, others found that PPF or ITF involvement was not an independent risk factor for worse outcome when compared to T4b tumors 194 .…”

Outcomes of management of sinonasal malignancies at a dedicated cancer institution: A retrospective study

“…[ 1 ] The most common histologies are squamous cell carcinoma followed by adenocarcinoma and adenoid cystic carcinoma etc. [ 15 16 17 18 19 20 21 ] Early staged tumours can be managed endoscopically[ 22 23 ] whereas open surgical approaches such as craniofacial resection, maxillectomy, midface degloving, lateral rhinotomy, and orbital exenteration deemed necessary for advanced tumours. It is quite challenging to perform surgery with clear margins due to complex anatomy of the region,[ 24 25 26 27 ] and hence, adjuvant radiotherapy becomes a very useful treatment modality in such cases.…”

Oncologic outcome of multimodality treatment for sinonasal malignancies: An 18-year experience

“…Employment of systemic therapy for locally advanced disease could result in better outcomes and optimize the therapeutic armamentarium ( 33 ). Post-operative adjuvant therapy has a well-established role in the treatment of most craniofacial malignancies ( 34 – 37 ). The National Comprehensive Cancer Network suggested that adjuvant therapy should be applied except for T1 stage patients ( 38 ).…”